NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, News & Analysis

Today's Range N/A
50-Day Range
MA: $6.30
52-Week Range N/A
Volume293,033 shs
Average Volume482,230 shs
Market Capitalization$181.82 million
P/E RatioN/A
Dividend YieldN/A
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMY



Sales & Book Value

Annual Sales$26.77 million
Book Value$0.13 per share


Net Income$-11,980,000.00


Market Cap$181.82 million
Next Earnings DateN/A

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) issued its quarterly earnings data on Monday, August, 6th. The specialty pharmaceutical company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.24. The specialty pharmaceutical company earned $10.38 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 16.81% and a negative return on equity of 231.16%. View Imprimis Pharmaceuticals' Earnings History.

What price target have analysts set for IMMY?

2 analysts have issued 1-year price objectives for Imprimis Pharmaceuticals' shares. Their forecasts range from $10.00 to $11.50. On average, they anticipate Imprimis Pharmaceuticals' stock price to reach $10.75 in the next twelve months. View Analyst Price Targets for Imprimis Pharmaceuticals.

What is the consensus analysts' recommendation for Imprimis Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Imprimis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Imprimis Pharmaceuticals.

Has Imprimis Pharmaceuticals been receiving favorable news coverage?

News headlines about IMMY stock have trended negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Imprimis Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

What other stocks do shareholders of Imprimis Pharmaceuticals own?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 45)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)
  • Mr. John P. Saharek, Chief Commercial Officer (Age 58)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

How do I buy shares of Imprimis Pharmaceuticals?

Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $0.00 and generates $26.77 million in revenue each year. The specialty pharmaceutical company earns $-11,980,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. View Additional Information About Imprimis Pharmaceuticals.

What is Imprimis Pharmaceuticals' official website?

The official website for Imprimis Pharmaceuticals is

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]

MarketBeat Community Rating for Imprimis Pharmaceuticals (NASDAQ IMMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  357
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel